Peginterferon
- PDF / 123,273 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 115 Downloads / 168 Views
1
S
Various toxicities: case report A 57-year-old woman with chronic hepatitis C virus (HCV) infection developed microangiopathy, sarcoidosis, candidiasis pneumonia and hyperglycaemia during treatment with peginterferon. The woman started receiving peginterferon 180 µg/week with ribavirin for persistent hypertransaminasaemia. She was also receiving acenocoumarol for atrial fibrillation. In her sixth month of treatment, she developed candidiasis involving her mouth, lips, hands and feet. The woman’s symptoms improved after 2 weeks of fluconazole treatment. At the start of her seventh month of treatment, she developed severe ulcerous, erosive microangiopathy that was resistant to treatment. Flu-like symptoms subsequently developed, including fever and tracheobronchitis, followed by febrile bilateral nodular pneumonia; sarcoidosis was suspected. Corticosteroids were started, but severe hyperglycaemia developed. Insulin was added to her treatment. Hypertransaminasaemia reappeared in her eight month of treatment, and was attributed to prolonged corticosteroid use. Corticosteroids were decreased, but sarcoidosis worsened after 14 days. Her condition was refractory to antibacterials and symptomatic treatment. Peginterferon was withdrawn in her ninth month of treatment. Four weeks later, her microangiopathy had improved, and subsequently resolved completely. Sarcoidosis and hyperglycaemia were under complete control at last follow-up. Como N, et al. Dynamic of PEG interferon-related pathologies, which induced interruption of treatment, in a patient with viral hepatitis C. 14th International Congress on Infectious Diseases : abstr. ISE.331, 9 Mar 2010. Available from: 803011140 URL: http://www.isid.org - Albania
0114-9954/10/1297-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 17 Apr 2010 No. 1297
Data Loading...
